26 completed, 4 unknown, 2 recruiting, 1 active not recruiting. 35 Phase 2, 5 Phase 1, 3 Phase 3.
Follow Diphtheria: new trials by email Literature Review of Diphtheria trials Research Report on Diphtheria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) Tdap vaccine, Placebo - Pertussis (Whooping Cough), Diphtheria | Phase 2 | Recruiting | Changchun BCHT Biotechnology Co. | 420 | 2026-08-12 | 2026-10-26 |
| Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine low-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), high-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), Tetanus, Diphtheria and Acellular Pertussis Vaccine - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus | Phase 1 / Phase 2 | Not yet recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 660 | 2026-03-12 | 2026-02-18 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)), 23-valent Pneumococcal Polysaccharide Vaccine (PPV23), Tdcp - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | CanSino Biologics Inc. | 1820 | 2024-12-20 | 2026-08-26 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination | Phase 2 | Completed | ABO Holdings, Inc. | 107 | 2023-05-05 | 2026-07-02 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
| A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults GC3111 vaccine, Boostrix® vaccine - Tetanus, Diphtheria | Phase 2 | Unknown | Green Cross Corporation | 213 | 2019-10-14 | 2020-01-23 |
| A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS RSV Vaccine, Tdap, Placebo - Respiratory Tract Infection | Phase 2 | Completed | Pfizer | 713 | 2019-10-01 | 2021-02-15 |
| Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide - Clostridium Difficile Immunisation, Diphtheria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 399 | 2019-01-24 | 2025-05-21 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine Biological: GC3111 vaccine, Biological: Boostrix® vaccine - Tetanus, Diphtheria | Phase 1 / Phase 2 | Unknown | Green Cross Corporation | 220 | 2016-06-01 | 2016-11-07 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3 - Tetanus, Diphtheria | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1363 | 2015-10-22 | 2022-03-23 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis - Pertussis, Tetanus | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 43 | 2012-09-01 | 2014-02-21 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis | Phase 2 | Completed | GlaxoSmithKline | 721 | 2010-12-09 | 2018-08-20 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose GSK2202083A vaccine, Infanrix hexa™, Menjugate™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 391 | 2010-08-18 | 2020-01-21 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™ - Tetanus, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 480 | 2010-05-17 | 2018-08-20 |
| Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers GSK2036874A vaccine, Zilbrix™/Hib vaccine, Poliorix™ - Haemophilus Influenzae Type b, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 312 | 2010-05-13 | 2019-10-01 |
Showing 20 of 35. Sign in to see all of them.
Tetanus (35) · Hepatitis B (22) · Whooping Cough (21) · Poliomyelitis (20) · Haemophilus Infections (19) · Meningitis, Meningococcal (1) · Respiratory Tract Infections (1)
Actinomycetales Infections (35) · Bacterial Infections (35) · Bacterial Infections and Mycoses (35) · Clostridium Infections (35) · Corynebacterium Infections (35) · Gram-Positive Bacterial Infections (35) · Infections (35) · Gram-Negative Bacterial Infections (32) · Virus Diseases (24) · Blood-Borne Infections (22) · Communicable Diseases (22) · DNA Virus Infections (22) · Digestive System Diseases (22) · Hepadnaviridae Infections (22) · Hepatitis (22)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (9) · Tetanus Toxoid (7) · Vaccines, Combined (4) · 13-valent pneumococcal vaccine (3) · Diphtheria-Tetanus-acellular Pertussis Vaccines (3) · Poliovirus Vaccine, Inactivated (3) · Boostrix (2) · adacel (2) · 10-valent pneumococcal vaccine (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (1) · Hepatitis B Vaccines (1) · Hiberix (1)
GlaxoSmithKline (15) · Sanofi Pasteur, a Sanofi Company (5) · LG Chem (4) · Green Cross Corporation (2) · Institute of Medical Biology, Chinese Academy of Medical Sciences (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ABO Holdings, Inc. (1) · CanSino Biologics Inc. (1) · Changchun BCHT Biotechnology Co. (1) · Pfizer (1) · Sanofi (1)
United States (7) · Philippines (5) · China (4) · Finland (4) · Canada (3) · South Korea (3) · Dominican Republic (2) · Germany (2) · Poland (2) · Argentina (1) · France (1) · Japan (1) · Mali (1) · Slovakia (1)
Adam Thaler, DO (1) · Edison Alberto, MD (1) · Hanqing He (1) · Jiawei Xu (1) · Josefina Carlos, MD (1) · Wenge Tang (1)
PMID 28340322, PMID 20657177, PMID 21372751, PMID 23241989, PMID 24346596, PMID 25540274, PMID 34637519, PMID 38586589
2009 (1), 2016 (1)